- Home
- ABOS vs HURA Comparison
ABOS vs HURA Comparison
Compare ABOS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABOS | HURA |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 160.5M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ABOS | HURA |
|---|---|---|
| Price | $1.68 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.60 | ★ $8.04 |
| AVG Volume (30 Days) | ★ 547.5K | 211.6K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.41 |
| 52 Week High | $3.60 | $3.43 |
Technical Indicators
Market Signals| Indicator | ABOS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 26.69 | 36.04 |
| Support Level | $1.67 | $1.27 |
| Resistance Level | $2.77 | $1.83 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 10.00 | 11.70 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.